Hypersensitivity - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hypersensitivity - Pipeline Review, H2 2016’, provides an overview of the Hypersensitivity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypersensitivity

The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects

The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hypersensitivity

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hypersensitivity

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adamis Pharmaceuticals Corporation

Adverum Biotechnologies, Inc.

Aimmune Therapeutics, Inc.

Alfacyte Ltd

ALK-Abello A/S

Allakos Inc.

Allergopharma GmbH & Co. KG

Allergy Therapeutics Plc

Amgen Inc. ...

Adamis Pharmaceuticals Corporation

Adverum Biotechnologies, Inc.

Aimmune Therapeutics, Inc.

Alfacyte Ltd

ALK-Abello A/S

Allakos Inc.

Allergopharma GmbH & Co. KG

Allergy Therapeutics Plc

Amgen Inc.

Anacor Pharmaceuticals, Inc.

AnaptysBio, Inc.

Anergis SA

Antigen Express, Inc.

Aravax Pty Ltd

Array BioPharma Inc.

ASIT biotech s.a.

AskAt Inc.

Astellas Pharma Inc.

BioLingus AG

Biomay AG

Biotec Pharmacon ASA

Boehringer Ingelheim GmbH

Circassia Pharmaceuticals Plc

DBV Technologies S.A.

DNJ Pharma, Inc.

EA Pharma Co Ltd

Enzene Biosciences Ltd.

EpiVax, Inc.

Fountain Biopharma Inc.

HAL Allergy BV

iCeutica, Inc.

ImmunoFrontier, Inc.

Immunomic Therapeutics, Inc.

Immupharma Plc

InMed Pharmaceuticals Inc.

Interprotein Corporation

Japan Tobacco Inc.

JW Pharmaceutical Corporation

Laboratorios LETI S.L.

Monosol Rx, LLC

NAL Pharmaceuticals Ltd.

Neovacs SA

Novartis AG

Ono Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals Inc

REGiMMUNE Corporation

Roxall Medizin GmbH

Sanofi

Sealife PHARMA GMBH

Stallergenes Greer plc

Stallergenes SAS

Swecure AB

Therabron Therapeutics, Inc.

Thesan Pharmaceuticals, Inc.

Toleranzia AB

United Biomedical, Inc.

United BioPharma, Inc.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Hypersensitivity Overview 7

Therapeutics Development 8

Hypersensitivity - Therapeutics under Development by Companies 10

Hypersensitivity - ...

Table of Contents

Table of Contents 2

Introduction 6

Hypersensitivity Overview 7

Therapeutics Development 8

Hypersensitivity - Therapeutics under Development by Companies 10

Hypersensitivity - Therapeutics under Investigation by Universities/Institutes 16

Hypersensitivity - Pipeline Products Glance 17

Hypersensitivity - Products under Development by Companies 21

Hypersensitivity - Products under Investigation by Universities/Institutes 30

Hypersensitivity - Companies Involved in Therapeutics Development 31

Hypersensitivity - Therapeutics Assessment 88

Drug Profiles 100

Hypersensitivity - Dormant Projects 272

Hypersensitivity - Discontinued Products 283

Hypersensitivity - Product Development Milestones 284

Appendix 297

List of Tables

List of Tables

Number of Products under Development for Hypersensitivity, H2 2016 23

Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016 ...

List of Tables

Number of Products under Development for Hypersensitivity, H2 2016 23

Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016 24

Number of Products under Development by Companies, H2 2016 26

Number of Products under Development by Companies, H2 2016 (Contd..1) 27

Number of Products under Development by Companies, H2 2016 (Contd..2) 28

Number of Products under Development by Companies, H2 2016 (Contd..3) 29

Number of Products under Development by Companies, H2 2016 (Contd..4) 30

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Late Stage Development, H2 2016 32

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Development, H2 2016 34

Comparative Analysis by Unknown Stage Development, H2 2016 35

Products under Development by Companies, H2 2016 36

Products under Development by Companies, H2 2016 (Contd..1) 37

Products under Development by Companies, H2 2016 (Contd..2) 38

Products under Development by Companies, H2 2016 (Contd..3) 39

Products under Development by Companies, H2 2016 (Contd..4) 40

Products under Development by Companies, H2 2016 (Contd..5) 41

Products under Development by Companies, H2 2016 (Contd..6) 42

Products under Development by Companies, H2 2016 (Contd..7) 43

Products under Development by Companies, H2 2016 (Contd..8) 44

Products under Investigation by Universities/Institutes, H2 2016 45

Hypersensitivity - Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 46

Hypersensitivity - Pipeline by Adverum Biotechnologies, Inc., H2 2016 47

Hypersensitivity - Pipeline by Aimmune Therapeutics, Inc., H2 2016 48

Hypersensitivity - Pipeline by Alfacyte Ltd, H2 2016 49

Hypersensitivity - Pipeline by ALK-Abello A/S, H2 2016 50

Hypersensitivity - Pipeline by Allakos Inc., H2 2016 51

Hypersensitivity - Pipeline by Allergopharma GmbH & Co. KG, H2 2016 52

Hypersensitivity - Pipeline by Allergy Therapeutics Plc, H2 2016 53

Hypersensitivity - Pipeline by Amgen Inc., H2 2016 54

Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 55

Hypersensitivity - Pipeline by AnaptysBio, Inc., H2 2016 56

Hypersensitivity - Pipeline by Anergis SA, H2 2016 57

Hypersensitivity - Pipeline by Antigen Express, Inc., H2 2016 58

Hypersensitivity - Pipeline by Aravax Pty Ltd, H2 2016 59

Hypersensitivity - Pipeline by Array BioPharma Inc., H2 2016 60

Hypersensitivity - Pipeline by ASIT biotech s.a., H2 2016 61

Hypersensitivity - Pipeline by AskAt Inc., H2 2016 62

Hypersensitivity - Pipeline by Astellas Pharma Inc., H2 2016 63

Hypersensitivity - Pipeline by BioLingus AG, H2 2016 64

Hypersensitivity - Pipeline by Biomay AG, H2 2016 65

Hypersensitivity - Pipeline by Biotec Pharmacon ASA, H2 2016 66

Hypersensitivity - Pipeline by Boehringer Ingelheim GmbH, H2 2016 67

Hypersensitivity - Pipeline by Circassia Pharmaceuticals Plc, H2 2016 68

Hypersensitivity - Pipeline by DBV Technologies S.A., H2 2016 69

Hypersensitivity - Pipeline by DNJ Pharma, Inc., H2 2016 70

Hypersensitivity - Pipeline by EA Pharma Co Ltd, H2 2016 71

Hypersensitivity - Pipeline by Enzene Biosciences Ltd., H2 2016 72

Hypersensitivity - Pipeline by EpiVax, Inc., H2 2016 73

Hypersensitivity - Pipeline by Fountain Biopharma Inc., H2 2016 74

Hypersensitivity - Pipeline by HAL Allergy BV, H2 2016 75

Hypersensitivity - Pipeline by iCeutica, Inc., H2 2016 76

Hypersensitivity - Pipeline by ImmunoFrontier, Inc., H2 2016 77

Hypersensitivity - Pipeline by Immunomic Therapeutics, Inc., H2 2016 78

Hypersensitivity - Pipeline by Immupharma Plc, H2 2016 79

Hypersensitivity - Pipeline by InMed Pharmaceuticals Inc., H2 2016 80

Hypersensitivity - Pipeline by Interprotein Corporation, H2 2016 81

Hypersensitivity - Pipeline by Japan Tobacco Inc., H2 2016 82

Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H2 2016 83

Hypersensitivity - Pipeline by Laboratorios LETI S.L., H2 2016 84

Hypersensitivity - Pipeline by Monosol Rx, LLC, H2 2016 85

Hypersensitivity - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 86

Hypersensitivity - Pipeline by Neovacs SA, H2 2016 87

Hypersensitivity - Pipeline by Novartis AG, H2 2016 88

Hypersensitivity - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 89

Hypersensitivity - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 90

Hypersensitivity - Pipeline by REGiMMUNE Corporation, H2 2016 91

Hypersensitivity - Pipeline by Roxall Medizin GmbH, H2 2016 92

Hypersensitivity - Pipeline by Sanofi, H2 2016 93

Hypersensitivity - Pipeline by Sealife PHARMA GMBH, H2 2016 94

Hypersensitivity - Pipeline by Stallergenes Greer plc, H2 2016 95

Hypersensitivity - Pipeline by Stallergenes SAS, H2 2016 96

Hypersensitivity - Pipeline by Swecure AB, H2 2016 97

Hypersensitivity - Pipeline by Therabron Therapeutics, Inc., H2 2016 98

Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016 99

Hypersensitivity - Pipeline by Toleranzia AB, H2 2016 100

Hypersensitivity - Pipeline by United Biomedical, Inc., H2 2016 101

Hypersensitivity - Pipeline by United BioPharma, Inc., H2 2016 102

Assessment by Monotherapy Products, H2 2016 103

Assessment by Combination Products, H2 2016 104

Number of Products by Stage and Target, H2 2016 106

Number of Products by Stage and Mechanism of Action, H2 2016 109

Number of Products by Stage and Route of Administration, H2 2016 112

Number of Products by Stage and Molecule Type, H2 2016 114

Hypersensitivity - Dormant Projects, H2 2016 287

Hypersensitivity - Dormant Projects (Contd..1), H2 2016 288

Hypersensitivity - Dormant Projects (Contd..2), H2 2016 289

Hypersensitivity - Dormant Projects (Contd..3), H2 2016 290

Hypersensitivity - Dormant Projects (Contd..4), H2 2016 291

Hypersensitivity - Dormant Projects (Contd..5), H2 2016 292

Hypersensitivity - Dormant Projects (Contd..6), H2 2016 293

Hypersensitivity - Dormant Projects (Contd..7), H2 2016 294

Hypersensitivity - Dormant Projects (Contd..8), H2 2016 295

Hypersensitivity - Dormant Projects (Contd..9), H2 2016 296

Hypersensitivity - Dormant Projects (Contd..10), H2 2016 297

Hypersensitivity - Discontinued Products, H2 2016 298

List of Figures

List of Figures

Number of Products under Development for Hypersensitivity, H2 2016 23

Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016 ...

List of Figures

Number of Products under Development for Hypersensitivity, H2 2016 23

Number of Products under Development for Hypersensitivity - Comparative Analysis, H2 2016 24

Number of Products under Development by Companies, H2 2016 25

Number of Products under Investigation by Universities/Institutes, H2 2016 31

Comparative Analysis by Late Stage Development, H2 2016 32

Comparative Analysis by Clinical Stage Development, H2 2016 33

Comparative Analysis by Early Stage Products, H2 2016 34

Assessment by Monotherapy Products, H2 2016 103

Assessment by Combination Products, H2 2016 104

Number of Products by Top 10 Targets, H2 2016 105

Number of Products by Stage and Top 10 Targets, H2 2016 105

Number of Products by Top 10 Mechanism of Actions, H2 2016 108

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 108

Number of Products by Top 10 Routes of Administration, H2 2016 111

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 111

Number of Products by Top 10 Molecule Types, H2 2016 113

Number of Products by Stage and Top 10 Molecule Types, H2 2016 113

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports